NEW YORK, May 11, 2020 -- Avenue Therapeutics, Inc. (NASDAQ: ATXI) (“Avenue”), a company focused on the development of intravenous (“IV”) tramadol for the U.S. market, today.
Avenue Therapeutics, Inc. (ATXI) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank 1 (Strong Buy).
Avenue Therapeutics, Inc. (ATXI) (“Avenue”), a company focused on the development of intravenous (“IV”) tramadol for the U.S. market, announced today that its Phase 1 data on intravenous (IV) tramadol has been published in the peer-reviewed journal Clinical Pharmacology in Drug Development. Based on the results of the study, Avenue chose the IV tramadol 50 mg dosing regimen for Phase 3 development. The objective of this Phase 1, open-label, single investigational center, three-treatment, three-period, multidose crossover study was to compare the pharmacokinetics of two novel IV tramadol dosing regimens to oral tramadol 100 mg given every six hours, the highest approved oral dosage in the United States.
The logic behind the breakout strategy for stock selection is to identify stocks are trading within a narrow band.
Is (ATXI) Outperforming Other Medical Stocks This Year?
Top Ranked Momentum Stocks to Buy for April 27th
Avenue Therapeutics (ATXI) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
NEW YORK, March 30, 2020 -- Avenue Therapeutics, Inc. (NASDAQ: ATXI) (“Avenue”), a company focused on the development of intravenous (“IV”) tramadol for the U.S. market, today.
We at Insider Monkey have gone over 821 13F filings that hedge funds and prominent investors are required to file by the SEC The 13F filings show the funds' and investors' portfolio positions as of March 31st, near the height of the coronavirus market crash. In this article, we look at what those funds think […]
NEW YORK, Feb. 13, 2020 -- Avenue Therapeutics, Inc. (NASDAQ: ATXI) (“Avenue”), a company focused on the development of intravenous (“IV”) tramadol for the U.S. market, today.
The Zacks Analyst Blog Highlights: Cue Biopharma, PJT Partners, Avenue Therapeutics, SpartanNash and Gaia
Small Drug Industry Prospects Bright Amid Coronavirus Gloom
Want to try an out-of-the-box approach to earn handsome returns? Tap these stocks with explosive relative price strength.
Avenue (ATXI) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
The NDA for IV tramadol is based on positive results from two pivotal Phase 3 clinical efficacy and safety trials in patients following bunionectomy and abdominoplasty surgeries, as well as an open-label safety study with a total of more than 500 patients who received the IV tramadol 50 mg dosing regimen. In addition, the NDA includes an epidemiology study on abuse of tramadol in the U.S. and in certain European countries where IV tramadol is available. “As a potential alternative that could reduce the use of conventional opioids, IV tramadol may fill a gap between IV acetaminophen/NSAIDs and IV conventional narcotics in the acute pain space,” said Lucy Lu, M.D., Avenue’s President and Chief Executive Officer.
The e-poster (816) titled “Intravenous Tramadol is Effective in Management of Postoperative Pain Following Abdominoplasty: A 3-arm Randomized Controlled Trial” presents data from the Phase 3 abdominoplasty study and can be found here. This Phase 3, multicenter, double-blind, placebo and active controlled trial evaluated the efficacy and safety of IV tramadol in 370 patients following abdominoplasty surgery. Patients were randomized to a postoperative regimen of IV tramadol 50 mg, placebo or IV morphine 4 mg. The primary endpoint of the study assessed the analgesic efficacy of IV tramadol compared to placebo as measured by SPID24 (sum of pain intensity differences through 24 hours post first dose).
The following is a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks that hit 52-week highs on Dec. 12.) Allergan plc (NYSE: AGN ) Amgen, Inc. (NASDAQ: ...
A handful of small-cap stocks have skyrocketed defying the coronavirus-induced market mayhem and extreme volatility.
NEW YORK, Nov. 04, 2019 -- Avenue Therapeutics, Inc. (NASDAQ: ATXI) (“Avenue”), a company focused on the development of intravenous (“IV”) tramadol for the U.S. market, today.
Zacks.com featured highlights include: Avenue Therapeutics, Glu Mobile, Yamana Gold and Z Holdings